Author  
Place of duty  
Title   성인 급성 골수성 백혈병에 대한 Augmented TAD 복합 화학요법 및 강화요법의 치료 효과 ( Treatment with Augmented TAD Combination Chemotherapy and Consolidation in Patient with Acute Myelogenous Leukemia )
Publicationinfo   1991 Jan; 023(04): 798-806.
Key_word   Acute myelogenous leukemia, Augmented TAD regiman
Full-Text  
Abstract   In the past 20 years, there has been substantial progress in the treatment of patients with acute myelogenous leukemia. Intensive induction chemotherapy using cytosine arabinoside and daunorubicin could produce remission in 60 to 85 percent of patients. A retrospective study was performed for 21 patients with acute myelogenous leukemia, who were treated with augmented TAD(3-10) regimen as a remission induction chemothecapy at Soonchunhyang Univer- sity Hospital from March 1987 to July 1991. Those who achieved complete remission received monthly altenative consolidation chemothecapy. A complete remission rate of 85.7%(l8/21) was obtained. Median remission duration was 13.14+ months and median survival was 15.11+' months in patient with complete remission. Mild to moderate degree of toxicities including nausea, vomiting, alopecia, stomatitis, diarrhea and hepatotoxicity were demonstrated. One was expired due to therapy related hepatotoxicity. These results suggest that the augmented TAD regimen is more effective than classical TAD regimen but this remains investigational at present and requires the prospective randomized double blind study.
저 자   김도진(Do Jin Kim),황정실(Jung Sil Whang),원종호(Jong Ho Won),홍대식(Dae Sik Hong),박희숙(Hee Sook Park),김원배(Won Bae Kim)